17:I[66739,["/_next/static/chunks/0.3dg.jzl0xwf.js?dpl=dpl_3RxvMhdoqChZq1Vee41wPR23ae8V","/_next/static/chunks/0skdv12y78fnh.js?dpl=dpl_3RxvMhdoqChZq1Vee41wPR23ae8V","/_next/static/chunks/10dnvbzcepzg2.js?dpl=dpl_3RxvMhdoqChZq1Vee41wPR23ae8V","/_next/static/chunks/0w-9dtq49e_fk.js?dpl=dpl_3RxvMhdoqChZq1Vee41wPR23ae8V","/_next/static/chunks/1331nw5i_3lcb.js?dpl=dpl_3RxvMhdoqChZq1Vee41wPR23ae8V","/_next/static/chunks/053zyoym-_i67.js?dpl=dpl_3RxvMhdoqChZq1Vee41wPR23ae8V"],"default"] 19:I[38632,["/_next/static/chunks/0qqtp3r0h7kah.js?dpl=dpl_3RxvMhdoqChZq1Vee41wPR23ae8V","/_next/static/chunks/0iukvycbd42rl.js?dpl=dpl_3RxvMhdoqChZq1Vee41wPR23ae8V"],"IconMark"] 18:T509,

High‑risk MDS and AML continue to challenge clinicians, with limited durable responses and few options for older or treatment‑refractory patients. In this sponsored episode of The Top Line, host Stephanie Butler is joined by Dr. Amer Zeidan, Professor of Internal Medicine at Yale School of Medicine, to unpack new ASCO 2026 data that are drawing attention across the myeloid malignancies field.

The discussion focuses on mesutoclax, a novel oral BCL‑2 inhibitor evaluated in combination with azacitidine. Dr. Zeidan breaks down early findings showing a 100% objective response rate with CR rate of 40% per IWG 2006 criteria and 90% composite complete response with CR in 60% in treatment‑naïve high‑risk MDS, along with strong efficacy and encouraging safety signals in AML, with over 80% composite CR, and with potent activity in TP53 mutant, as well as zero death within 30 or 60 days and rapid cytopenia recovery.

Listeners will hear how mesutoclax’s potency, selectivity, and pharmacokinetic profile may overcome key limitations of existing BCL‑2 inhibitors, and what these results could mean for future frontline treatment strategies.

See omnystudio.com/listener for privacy information.

Mesutoclax points to possible shift in high-risk MDS and AML (Sponsored)

The Top Line

Mesutoclax points to possible shift in high-risk MDS and AML (Sponsored)